It's been a fruitful week for Ebola vaccines, with progress reported ranging from phase III to the preclinical arena. Clinically, the first phase III efficacy trial of an Ebola vaccine got under way in Guinea this week. VSV-EBOV, which Merck & Co. Inc. licensed from Newlink Genetics Corp., is being tested in a two-step trial.